Latest News and Press Releases

PRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...

TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2’22Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by...

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage...

TYRVAYA Now Covered by Commercial Prescription Drug Plans Managed by the Nation’s Top Three Pharmacy Benefit Manager (PBM) Group Purchasing Organizations (GPOs)Expanding Patient Access Programs to...

Plan to Continue to Drive TYRVAYA® Launch with Approximately 150-200 Field-Based Sales Resources Plan Expected to Deliver Expense Savings of Approximately $6-8 Million in the Second Half of 2022...

PRINCETON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization...

TYRVAYA® Nasal Spray Net Product Revenue of $2.7 Million in Q1’22Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care...

PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of...

PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and...

PRINCETON, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and...